摘要
Glaucoma is a disease that causes irreversible blindness. Reducing intraocular pressure(IOP) is the main treatment at present. Nitric oxide(NO), an endogenous gas signaling molecule, can increase aqueous humor outflow facility, inhibit aqueous humor production thereby reducing IOP, as well as regulate eye blood flow and protect the optic nerve. Therefore, NO donating antiglaucoma drugs have broad research prospects. In this review, we summarize NO-mediated therapy for glaucoma, and the state of the art of some NO donating molecules, including latanoprostene bunod in market and some other candidate compounds, for the intervention of glaucoma, as well as prospects and challenges ahead in this field.
基金
the National Natural Science Foundation of China (Nos. 81822041, 21977116,81673305, and 81773573)
National Science & Technology Major Project “Key New Drug Creation and Manufacturing Program” (No.2018ZX09711002-006-013)
the open project of State Key Laboratory of Natural Medicines (No. SKLNMZZCX201824)
State Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia Fund (No. SKL-HIDCA-2018-1)
part of the work was supported by Postgraduate Research & Practice Innovation Program of Jiangsu Province (No. KYCX18_0795)。
